University of California San Diego

$1M Gift Speeds COVID-19 Testing and Tracking at UC San Diego

Funds from the John and Mary Tu Foundation support the work of translational research virologist Davey Smith, M.D.

Newswise — A $1 million gift from the John and Mary Tu Foundation is helping to increase the number of people tested for COVID-19, as well as develop new ways to track and treat the virus. The award supports the clinical research activities of University of California San Diego translational research virologist Davey Smith, M.D., M.A.S., who is advancing new diagnostics, therapies and ways to monitor the spread of the virus.

“What we are trying to do is save lives,” said John Tu regarding the creation of the John and Mary Tu Foundation COVID-19 Response Fund. “It’s very simple: with this research, Dr. Smith is working on behalf of everybody, to save us, to save the world.”

“At this critical time during the COVID-19 pandemic, the generosity of the John and Mary Tu Foundation has an immediate positive impact on our efforts,” said Chancellor Pradeep K. Khosla. “Their support allows experts like Davey Smith to quickly mobilize to mitigate the spread of the virus and develop treatments for those affected.”

At the onset of the pandemic, Smith and his team immediately began to investigate methods that would increase the efficiency of testing as well as understand the disease process—how does the virus mutate and spread within a population? Through sequencing the virus, he is able to track the disease as it spreads into vulnerable populations, which informs the best means for contact tracing (a process of supporting patients and warning contacts of exposure in order to stop chains of transmission). Smith is also leading clinical trials to test new drugs for treatment of COVID-19 for those who have moderately severe cases.

According to Smith, prior to this gift, he and his team had limited resources, which would have frozen their progress.  “Without the support of the John and Mary Tu Foundation, we would not have been able to continue in our CoV-2 lab-based and clinical research,” he explained. “The foundation saw that time was of the essence in this pandemic and that science was going to get us out of it. Now we are conducting a number of clinical trials, including those for vaccines, and have found new drugs that will likely move to treatments soon.”

As chief of UC San Diego’s Division of Infectious Diseases and Global Public Health and co-director of the San Diego Center for AIDS Research, Smith and his team are uniquely positioned to rapidly respond to the spread of COVID-19, as well as forecast the pandemic. “It’s not a matter of if a pandemic can happen, but when,” said Smith. “We need to bolster science, technology and capabilities to prepare for pandemics.”

Smith has been on the front lines as the virus evolves. He has leveraged core technologies and partnered with top clinical infectious disease specialists at UC San Diego to conduct diagnostic tests, identify and test new antiviral drugs, develop antibody therapies, and launch vaccine trials. Now, thanks to the new gift, he has the resources needed to speed COVID-19 discoveries, minimize exposure and save lives.

The gift from the John and Mary Tu Foundation strengthens UC San Diego’s efforts to respond to the pandemic. The university launched a COVID-19 Emergency Response Fund to address the greatest needs in this evolving situation, and move forward with research and health care efforts to better understand and respond to COVID-19. Learn more about the COVID-19 Emergency Response Fund and how your philanthropy – as part of the Campaign for UC San Diego – can help develop new treatments for those affected by the disease.  

Together, we are continuing our nontraditional path toward revolutionary ideas, unexpected answers, lifesaving discoveries and planet-changing impact. To learn more about the Campaign for UC San Diego, a university-wide comprehensive fundraising effort concluding in 2022, visit campaign.ucsd.edu.




Filters close

Showing results

110 of 4206
Newswise: Proteolytic Enzymes for Covid-19 Studied in 3D for the First Time in Thailand by Chula Biochemists
Released: 4-Dec-2020 8:45 AM EST
Proteolytic Enzymes for Covid-19 Studied in 3D for the First Time in Thailand by Chula Biochemists
Chulalongkorn University

A team of biochemists from Chulalongkorn University became the first researchers in Thailand to study proteolytic enzymes for the Covid–19 virus at a molecular level in 3D, possibly leading to the development of Covid–19 treatments.

Newswise: UC San Diego Bolsters Aggressive Return to Learn Plan to Prevent Outbreaks on Campus
Released: 4-Dec-2020 8:35 AM EST
UC San Diego Bolsters Aggressive Return to Learn Plan to Prevent Outbreaks on Campus
University of California San Diego

UC San Diego’s nationally recognized, evidence-based Return to Learn program employs a comprehensive suite of education, monitoring, testing, intervention and notification tools that no other university is using. And the program continues to expand—including a recent introduction of weekly self-administered student testing kits, growth of the campus’s wastewater viral monitoring program and widespread use of the cellphone-based CA COVID Notify exposure notification system.

Newswise: Pediatric ER Saw Steep Drop in Asthma Visits During Spring COVID-19 Lockdown
1-Dec-2020 8:00 AM EST
Pediatric ER Saw Steep Drop in Asthma Visits During Spring COVID-19 Lockdown
American Thoracic Society (ATS)

A new study published online in the Annals of the American Thoracic Society discusses a steep drop off from prior years in asthma-related emergency department (ED) visits at Boston Children’s Hospital during the spring 2020 COVID-19 surge and lockdown.

access_time Embargo lifts in 2 days
Embargo will expire: 9-Dec-2020 4:00 PM EST Released to reporters: 3-Dec-2020 4:50 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2020 4:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

access_time Embargo lifts in 2 days
Embargo will expire: 9-Dec-2020 4:00 PM EST Released to reporters: 3-Dec-2020 3:50 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 9-Dec-2020 4:00 PM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: 250384_web.jpg
Released: 3-Dec-2020 3:05 PM EST
Study finds COVID-19 hindering US academic productivity of faculty with young children
University of Tennessee Health Science Center

The academic productivity of higher education faculty In the United States in the science, technology, engineering, mathematics, and medicine (STEMM) fields with very young children suffered as a result of the stay-at-home orders during the early months of the coronavirus pandemic, according to a new study by researchers at the University of Tennessee Health Science Center, the University of Florida College of Medicine, and the University of Michigan School of Medicine.

Released: 3-Dec-2020 2:50 PM EST
Kidney disease leading risk factor for COVID-related hospitalization
Geisinger Health System

An analysis of Geisinger's electronic health records has revealed chronic kidney disease to be the leading risk factor for hospitalization from COVID-19.

Newswise: Identity Verification During the Age of COVID-19
Released: 3-Dec-2020 2:25 PM EST
Identity Verification During the Age of COVID-19
Homeland Security's Science And Technology Directorate

S&T's Biometric Technology Rally focused on the ability of acquisition systems and matching algorithms to recognize travelers without asking them to remove their masks, thereby reducing risk for frontline workers.

access_time Embargo lifts in 2 days
Embargo will expire: 10-Dec-2020 11:00 AM EST Released to reporters: 3-Dec-2020 2:20 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 10-Dec-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


Showing results

110 of 4206

close
2.41384